Ingestible Balloon Helps Patients Lose Weight
|
By HospiMedica International staff writers Posted on 04 Oct 2016 |
|
Image: An ingestible intragastric balloon system helps reduce weight (Photo courtesy of Obalon).
An ingestible intragastric balloon system facilitates weight loss in obese adults who failed to lose weight through diet and exercise.
The Obalon system consists of a balloon folded inside a capsule that is swallowed by the patient, with no sedation or anesthesia required. Once the balloon reaches the stomach, it is remotely inflated via an attached micro-catheter that is subsequently removed, leaving behind a buoyant balloon with a volume of 250cc (about the size of a small orange) that weighs less than six grams. Over the following three months of treatment, two additional balloons are swallowed and inflated, bringing the total maximum displaced volume to750cc.
The nonsurgical weight loss system is fully reversible throughout the course, and at the end of the six-month treatment period, all three balloons are mandatorily removed via endoscopy under conscious sedation. The system is intended for use as an adjunct to a moderate intensity diet and to a behavior modification program. The Obalon balloon system is a product of Obalon (Carlsbad, CA, USA), and has been approved by the U.S. Food and Drug Administration (FDA).
“We’re excited to bring this novel technology to the approximately 70 million adults in the United States who are struggling with obesity. For physicians, we believe that the Obalon technology represents an important new option for both their practices and their patients who are obese and looking to lose weight,” said Andy Rasdal, CEO of Obalon. “I’d also like to recognize the FDA for their efficient and interactive review of our product, which represents another option for physicians and patients in the battle against the obesity epidemic.”
“The clinical trial design for the Obalon balloon system was highly rigorous and the system demonstrated a favorable safety profile,” said Shelby Sullivan, MD, director of the gastroenterology bariatric and metabolic program at the University of Colorado School of Medicine (Aurora, USA). “We were also pleased to see that patients tolerated the administrations of the Obalon balloon remarkably well, with no recovery time needed. This is in contrast to other currently approved intragastric balloon devices, where most patients cannot immediately return to normal activities.”
Related Links:
Obalon
The Obalon system consists of a balloon folded inside a capsule that is swallowed by the patient, with no sedation or anesthesia required. Once the balloon reaches the stomach, it is remotely inflated via an attached micro-catheter that is subsequently removed, leaving behind a buoyant balloon with a volume of 250cc (about the size of a small orange) that weighs less than six grams. Over the following three months of treatment, two additional balloons are swallowed and inflated, bringing the total maximum displaced volume to750cc.
The nonsurgical weight loss system is fully reversible throughout the course, and at the end of the six-month treatment period, all three balloons are mandatorily removed via endoscopy under conscious sedation. The system is intended for use as an adjunct to a moderate intensity diet and to a behavior modification program. The Obalon balloon system is a product of Obalon (Carlsbad, CA, USA), and has been approved by the U.S. Food and Drug Administration (FDA).
“We’re excited to bring this novel technology to the approximately 70 million adults in the United States who are struggling with obesity. For physicians, we believe that the Obalon technology represents an important new option for both their practices and their patients who are obese and looking to lose weight,” said Andy Rasdal, CEO of Obalon. “I’d also like to recognize the FDA for their efficient and interactive review of our product, which represents another option for physicians and patients in the battle against the obesity epidemic.”
“The clinical trial design for the Obalon balloon system was highly rigorous and the system demonstrated a favorable safety profile,” said Shelby Sullivan, MD, director of the gastroenterology bariatric and metabolic program at the University of Colorado School of Medicine (Aurora, USA). “We were also pleased to see that patients tolerated the administrations of the Obalon balloon remarkably well, with no recovery time needed. This is in contrast to other currently approved intragastric balloon devices, where most patients cannot immediately return to normal activities.”
Related Links:
Obalon
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Medical-Grade Display
HL2316SHTB
POC Respiratory/Sore Throat Test
BIOFIRE SPOTFIRE (R/ST) Panel
Latest Critical Care News
- Inhaled Analgesic Matches Morphine for Prehospital Trauma Pain
- FDA Clears Tongue-Applied Neuromodulation System for Stroke Gait Rehabilitation
- Eye Test May Predict Return of Consciousness After Severe Brain Injury
- Medical Drone Program Improves Blood Access and Patient Survival
- AI System Enables Real-Time Sepsis Quality Assessment and Improves Adherence
- AI Detects Hidden ECG Marker of Sudden Cardiac Death
- FDA-Cleared AI Wearable Monitor Detects Opioid-Related Respiratory Risk in Hospitals
- Mitral Valve Repair Device Receives EU Approval for Functional Regurgitation
- AI Risk Score Reveals Hidden Hypertension-Related Organ Damage
- AI Tool Predicts Bronchopulmonary Dysplasia Risk in Preterm Infants
- Optical Brain Monitoring Predicts Neurodevelopmental Outcomes in Preterm Infants
- AI Tool Identifies Children With Pneumonia Requiring Hospital Care
- AI Ultrasound System Improves Safety of Blood–Brain Barrier Opening
- CE-Marked Smartphone AI Enables Autonomous Skin Cancer Assessment at Point of Care
- Handheld Optical Device Screens for Early Necrotizing Enterocolitis in Preterm Infants
- Home Blood Pressure Telemonitoring Linked to Fewer Cardiovascular Events
Channels
Artificial Intelligence
view channel
AI Trends Report Guides Responsible, Effective Healthcare Deployment
Hospitals are under growing pressure to adopt artificial intelligence tools that improve safety, efficiency, and continuity of care without compromising quality. At the same time, clinicians need clearer... Read more
Privacy-Preserving AI Protects Sensitive Information in ECG Data
Artificial intelligence applied to electrocardiography can extract more than cardiac rhythm. Algorithms can infer age, sex, race, and even identity from electrocardiogram (ECG) signals, creating privacy... Read more
Surgical Techniques
view channel
Aortic Arch Remodeling Device Improves Type I Dissection Repair
Acute DeBakey Type I aortic dissection is an emergent tear of the ascending aorta that can extend into the arch and descending thoracic aorta. Rapid ischemic complications and high early mortality make... Read more
Intravesical CAR T Therapy Shows Promise for Bladder Cancer Treatment
Bladder cancer is common and frequently recurs after initial therapy, exposing patients to repeated procedures and cumulative toxicity. High‑risk disease often progresses despite intravesical drugs or... Read more
Patient Care
view channel
AI Avatar Doctor Improves Patient Understanding Before Radiotherapy
Radiation oncology consultations require patients to grasp complex concepts quickly, yet anxiety and information overload often undermine understanding and informed consent. Poor comprehension can also... Read more
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Health IT
view channel
Digital Heart Model Supports Targeted Ablation in Atrial Fibrillation
Atrial fibrillation is an erratic, quivering heartbeat and a leading cause of stroke. Catheter ablation is widely used to interrupt arrhythmogenic tissue, yet many patients—especially with persistent ... Read more
AI Framework Helps Clinicians Create Trustworthy Risk Prediction Tools
Artificial intelligence (AI) is increasingly used to estimate risks for conditions such as sepsis, heart disease, and cancer, yet many models remain difficult for clinicians to interpret or trust.... Read more
Point of Care
view channel
AI Dermatology Platform Targets Early Detection of Non-Melanoma Skin Cancer
Keratinocyte skin cancers, including basal cell and squamous cell carcinoma, account for a substantial share of dermatology workload in the United States and require accurate triage to guide biopsy decisions.... Read more
Handheld AI Device for Point-of-Care Skin Lesion Assessment Receives CE Mark
DermaSensor (Miami, FL, USA) has received a Class IIb CE Mark for its handheld DermaSensor device, marking the start of the company’s global expansion strategy. The certification demonstrates conformity... Read more
Business
view channel
Danaher Completes Acquisition of Masimo to Expand Patient Monitoring Capabilities
Danaher Corporation (Washington, DC, USA) has completed its acquisition of Masimo Corporation (Irvine, CA, USA), a specialty diagnostics provider known for pulse oximetry and advanced patient monitoring... Read more
